necitumumab

Home
Ligands
necitumumab

GtoPdb Ligand ID: 8090

Synonyms: 11F8 | IMC-11F8 | LY3012211 | Portrazza®

necitumumab is an approved drug (FDA (2015), EMA (2016))

Comment: Necitumumab is a monoclonal antibody with clinical antineoplastic action [1-3].
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record.

View interactive charts of activity data across species

No information available.

Summary of Clinical Use
Necitumumab is being investigated in several clinical trials at various stages of development: solid tumours (Phase 1), metastatic colorectal cancer (Phase 2) and non-small-cell lung cancer (Phase 3, NCT00981058, for squamous cell NSCLC and NCT00982111, for nonsquamous NSCLC). Click here to link to ClinicalTrials.gov's complete listing of registered necitumumab trials. In November 2015, the US FDA approved necitumumab (in combination with the chemotherapeutics gemcitabine and cisplatin) to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) who have not previously received anti-lung cancer therapy.

Summary of Clinical Use

Necitumumab is being investigated in several clinical trials at various stages of development: solid tumours (Phase 1), metastatic colorectal cancer (Phase 2) and non-small-cell lung cancer (Phase 3, NCT00981058, for squamous cell NSCLC and NCT00982111, for nonsquamous NSCLC). Click here to link to ClinicalTrials.gov's complete listing of registered necitumumab trials.
In November 2015, the US FDA approved necitumumab (in combination with the chemotherapeutics gemcitabine and cisplatin) to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) who have not previously received anti-lung cancer therapy.

Mechanism Of Action and Pharmacodynamic Effects
Necitumumab targets the epidermal growth factor receptor (EGFR), inhibiting the receptor's tyrosine kinase activity and inhibiting growth of EGFR-expressing tumour cells [1].

Mechanism Of Action and Pharmacodynamic Effects

Necitumumab targets the epidermal growth factor receptor (EGFR), inhibiting the receptor's tyrosine kinase activity and inhibiting growth of EGFR-expressing tumour cells [1].